ArticleNature communications2022
SARS-CoV-2 transmission and impacts of unvaccinated-only screening in populations of mixed vaccination status.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 12 citations in OpenAlex.
- Article
- A Paper-Based Multiplexed Serological Test to Monitor Immunity against SARS-COV-2 Using Machine Learning.ACS nano · 2024Article
- Modeling the transmission mitigation impact of testing for infectious diseases.Science advances · 2024Article
- Modeling the Transmission Mitigation Impact of Testing for Infectious Diseases.medRxiv : the preprint server for health sciences · 2024Article
- Optimizing COVID-19 testing strategies on college campuses: Evaluation of the health and economic costs.PLoS computational biology · 2023Article
- SARS-CoV-2 self-test uptake and factors associated with self-testing during Omicron BA.1 and BA.2 waves in France, January to May 2022.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Article
- Optimized workplace risk mitigation measures for SARS-CoV-2 in 2022.Scientific reports · 2023Article
- Risk Factors Associated with the Spatiotemporal Spread of the SARS-CoV-2 Omicron BA.2 Variant - Shanghai Municipality, China, 2022.China CDC weekly · 2023Article
- Optimizing COVID-19 testing strategies on college campuses: evaluation of the health and economic costs.medRxiv : the preprint server for health sciences · 2022Article
- Update on COVID-19 and Effectiveness of a Vaccination Campaign in a Global Context.International journal of environmental research and public health · 2022Review
- SARS-CoV-2 transmission and impacts of unvaccinated-only screening in populations of mixed vaccination status.Nature communications · 2022Article
Corrections and comments
- Update of
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Screening programs that test only the unvaccinated population have been proposed and implemented to mitigate SARS-CoV-2 spread, implicitly assuming that the unvaccinated population drives transmission. To evaluate this premise and quantify the impact of unvaccinated-only screening programs, we introduce a model for SARS-CoV-2 transmission through which we explore a range of transmission rates, vaccine effectiveness scenarios, rates of prior infection, and screening programs. We find that, as vaccination rates increase, the proportion of transmission driven by the unvaccinated population decreases, such that most community spread is driven by vaccine-breakthrough infections once vaccine coverage exceeds 55% (omicron) or 80% (delta), points which shift lower as vaccine effectiveness wanes. Thus, we show that as vaccination rates increase, the transmission reductions associated with unvaccinated-only screening decline, identifying three distinct categories of impact on infections and hospitalizations. More broadly, these results demonstrate that effective unvaccinated-only screening depends on population immunity, vaccination rates, and variant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.